HK1048250A1 - 在治療充血性心力衰竭中使用的部分脂肪酸氧化抑制劑 - Google Patents
在治療充血性心力衰竭中使用的部分脂肪酸氧化抑制劑Info
- Publication number
- HK1048250A1 HK1048250A1 HK03100016.7A HK03100016A HK1048250A1 HK 1048250 A1 HK1048250 A1 HK 1048250A1 HK 03100016 A HK03100016 A HK 03100016A HK 1048250 A1 HK1048250 A1 HK 1048250A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- treatment
- fatty acid
- heart failure
- congestive heart
- acid oxidation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18356000P | 2000-02-18 | 2000-02-18 | |
US21990800P | 2000-07-21 | 2000-07-21 | |
PCT/US2001/004887 WO2001060348A2 (en) | 2000-02-18 | 2001-02-15 | Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1048250A1 true HK1048250A1 (zh) | 2003-03-28 |
Family
ID=26879274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK03100016.7A HK1048250A1 (zh) | 2000-02-18 | 2003-01-20 | 在治療充血性心力衰竭中使用的部分脂肪酸氧化抑制劑 |
Country Status (17)
Country | Link |
---|---|
US (2) | US6528511B2 (zh) |
EP (2) | EP2033633A3 (zh) |
JP (1) | JP2004505886A (zh) |
KR (1) | KR20020075801A (zh) |
CN (1) | CN1227004C (zh) |
AR (1) | AR033510A1 (zh) |
AU (1) | AU778203B2 (zh) |
BR (1) | BR0108452A (zh) |
CA (1) | CA2398691A1 (zh) |
HK (1) | HK1048250A1 (zh) |
IL (1) | IL151014A0 (zh) |
MX (1) | MXPA02007639A (zh) |
NO (1) | NO20023879D0 (zh) |
NZ (1) | NZ520780A (zh) |
TW (1) | TWI235655B (zh) |
WO (1) | WO2001060348A2 (zh) |
ZA (1) | ZA200206451B (zh) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2033633A3 (en) * | 2000-02-18 | 2009-07-08 | Cv Therapeutics, Inc. | Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
WO2003037323A2 (en) * | 2001-10-26 | 2003-05-08 | MEDIGENE AG Gesellschaft für Molekularbiologische Kardiologie und Onkologie | Inhibitors of the fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction |
ES2289153T7 (es) * | 2001-11-08 | 2009-06-18 | Atrium Medical Corporation | Dispositivo intraluminal con un revestimiento que contiene un agente terapeutico. |
US20030220344A1 (en) * | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
US8822473B2 (en) * | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
JP4546824B2 (ja) | 2002-05-21 | 2010-09-22 | ギリアード・パロ・アルト・インコーポレイテッド | 糖尿病を処置する方法 |
DE60328545D1 (de) * | 2002-12-05 | 2009-09-03 | Cv Therapeutics Inc | Substituierte Piperazinderivate und ihre Verwendung als Inhibitoren der Fettsäureoxidation |
JP2007514769A (ja) * | 2003-12-18 | 2007-06-07 | シーブイ・セラピューティクス・インコーポレイテッド | 1−アルカン−2−オール置換ピペラジンおよびピペリジン化合物 |
EP2298862B1 (en) † | 2004-03-22 | 2017-08-30 | Mesoblast International Sàrl | Mesenchymal stem cells and uses therefor |
US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
WO2006036970A2 (en) * | 2004-09-28 | 2006-04-06 | Atrium Medical Corporation | Method of thickening a coating using a drug |
US8367099B2 (en) | 2004-09-28 | 2013-02-05 | Atrium Medical Corporation | Perforated fatty acid films |
US20060088596A1 (en) * | 2004-09-28 | 2006-04-27 | Atrium Medical Corporation | Solubilizing a drug for use in a coating |
US8312836B2 (en) | 2004-09-28 | 2012-11-20 | Atrium Medical Corporation | Method and apparatus for application of a fresh coating on a medical device |
EP1811935B1 (en) | 2004-09-28 | 2016-03-30 | Atrium Medical Corporation | Heat cured gel and method of making |
US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US20090011116A1 (en) * | 2004-09-28 | 2009-01-08 | Atrium Medical Corporation | Reducing template with coating receptacle containing a medical device to be coated |
US9801982B2 (en) * | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
JP2008519770A (ja) * | 2004-11-09 | 2008-06-12 | シーブイ・セラピューティクス・インコーポレイテッド | 心不全の処置における左室リモデリングを逆転させるための少なくとも1種のリモデリング物質と併用するラノラジンの使用 |
WO2006099244A1 (en) * | 2005-03-11 | 2006-09-21 | Hong Kong Nitric Oxide Limited | Combination therapy for endothelial dysfunction, angina and diabetes |
US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
AU2006304590A1 (en) * | 2005-10-15 | 2007-04-26 | Atrium Medical Corporation | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
US7606617B2 (en) * | 2006-01-31 | 2009-10-20 | Cardiac Pacemakers, Inc. | Urinalysis for the early detection of and recovery from worsening heart failure |
AU2007293055B2 (en) * | 2006-09-08 | 2013-08-01 | Cardiopolymers, Inc. | Intramyocardial patterning for global cardiac resizing and reshaping |
EP2626091B1 (en) * | 2006-11-06 | 2016-09-28 | Atrium Medical Corporation | Coated surgical mesh |
US9492596B2 (en) * | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
CA2678319A1 (en) * | 2007-02-13 | 2008-08-21 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of coronary microvascular diseases |
US20090111826A1 (en) * | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
EP2117550A1 (en) * | 2007-02-13 | 2009-11-18 | CV Therapeutics Inc. | Use of ranolazine for the treatment of non-coronary microvascular diseases |
CA2678272A1 (en) * | 2007-02-13 | 2008-10-02 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of cardiovascular diseases |
WO2008116083A1 (en) * | 2007-03-22 | 2008-09-25 | Cv Therapeutics, Inc. | Use of ranolazine for elevated brain-type natriuretic peptide |
EP2146667A2 (en) * | 2007-04-11 | 2010-01-27 | Henry Ford Health System | Cardiac repair, resizing and reshaping using the venous system of the heart |
US20080299195A1 (en) * | 2007-05-31 | 2008-12-04 | Brent Blackburn | Use of ranolazine for elevated brain-type natriuretic peptide |
CN101066253B (zh) * | 2007-06-07 | 2011-01-05 | 北京本草天源药物研究院 | 一种雷诺嗪缓释片 |
WO2008154033A2 (en) * | 2007-06-11 | 2008-12-18 | Symphony Medical, Inc. | Cardiac patterning for improving diastolic function |
US20090012103A1 (en) | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
WO2009100380A1 (en) * | 2008-02-06 | 2009-08-13 | Cv Therapeutics, Inc. | Use of ranolazine for treating pain |
US20100292217A1 (en) * | 2009-05-14 | 2010-11-18 | Gilead Palo Alto, Inc. | Ranolazine for the treatment of cns disorders |
US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
MX2012003362A (es) * | 2009-09-25 | 2012-06-27 | Lupin Ltd | Composicion de liberación sostenida de ranolazina. |
EP2593141B1 (en) | 2010-07-16 | 2018-07-04 | Atrium Medical Corporation | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
ES2414384T3 (es) * | 2011-05-11 | 2013-07-19 | Ratiopharm Gmbh | Composición de liberación modificada que comprende ranolazina |
US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
CN104758265B (zh) * | 2014-01-07 | 2019-05-17 | 四川海思科制药有限公司 | 一种雷诺嗪缓释片药物组合物及其制备方法 |
FR3060567B1 (fr) | 2016-12-19 | 2019-05-24 | Ecole Normale Superieure De Lyon | Substrat de glycosidase fluorogene et procede de detection associe |
CN112438955A (zh) * | 2019-08-30 | 2021-03-05 | 深圳翰宇药业股份有限公司 | 一种雷诺嗪缓释组合物及其制备方法 |
GR1010510B (el) * | 2022-06-07 | 2023-07-20 | Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, | Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US4567264A (en) | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
US5001193A (en) | 1988-12-22 | 1991-03-19 | American Cyanamid | Epoxy adhesive for bonding of automotive parts made from bulk or sheet molding compound containing polymeric toughening agent and Mannich Base |
ATE223218T1 (de) * | 1989-06-23 | 2002-09-15 | Syntex Llc | Ranolazin und verwandte piperazine zum schutz der skelettmuskulatur |
US5455045A (en) | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
US6083532A (en) * | 1995-03-01 | 2000-07-04 | Duramed Pharmaceuticals, Inc. | Sustained release formulation containing three different types of polymers and tablet formed therefrom |
US6303607B1 (en) | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
EP2033633A3 (en) * | 2000-02-18 | 2009-07-08 | Cv Therapeutics, Inc. | Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
JP3980885B2 (ja) * | 2000-02-22 | 2007-09-26 | スィーヴィー セラピューティクス インコーポレイテッド | 置換ピペラジン化合物 |
-
2001
- 2001-02-15 EP EP08018568A patent/EP2033633A3/en not_active Withdrawn
- 2001-02-15 BR BR0108452-6A patent/BR0108452A/pt not_active Application Discontinuation
- 2001-02-15 JP JP2001559446A patent/JP2004505886A/ja active Pending
- 2001-02-15 US US09/784,559 patent/US6528511B2/en not_active Expired - Lifetime
- 2001-02-15 NZ NZ520780A patent/NZ520780A/en not_active IP Right Cessation
- 2001-02-15 AU AU41505/01A patent/AU778203B2/en not_active Ceased
- 2001-02-15 WO PCT/US2001/004887 patent/WO2001060348A2/en not_active Application Discontinuation
- 2001-02-15 KR KR1020027010748A patent/KR20020075801A/ko active Search and Examination
- 2001-02-15 CN CNB018051499A patent/CN1227004C/zh not_active Expired - Fee Related
- 2001-02-15 IL IL15101401A patent/IL151014A0/xx unknown
- 2001-02-15 MX MXPA02007639A patent/MXPA02007639A/es active IP Right Grant
- 2001-02-15 CA CA002398691A patent/CA2398691A1/en not_active Abandoned
- 2001-02-15 EP EP01912758A patent/EP1259230A2/en not_active Ceased
- 2001-02-16 TW TW090103593A patent/TWI235655B/zh not_active IP Right Cessation
- 2001-02-19 AR ARP010100738A patent/AR033510A1/es unknown
-
2002
- 2002-08-13 ZA ZA2002/06451A patent/ZA200206451B/en unknown
- 2002-08-15 NO NO20023879A patent/NO20023879D0/no not_active Application Discontinuation
- 2002-08-27 US US10/228,573 patent/US6677342B2/en not_active Expired - Lifetime
-
2003
- 2003-01-20 HK HK03100016.7A patent/HK1048250A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
KR20020075801A (ko) | 2002-10-05 |
AR033510A1 (es) | 2003-12-26 |
NZ520780A (en) | 2006-04-28 |
WO2001060348A3 (en) | 2002-01-31 |
AU778203B2 (en) | 2004-11-25 |
US6677342B2 (en) | 2004-01-13 |
JP2004505886A (ja) | 2004-02-26 |
BR0108452A (pt) | 2003-04-01 |
EP1259230A2 (en) | 2002-11-27 |
CN1420766A (zh) | 2003-05-28 |
ZA200206451B (en) | 2003-12-31 |
AU4150501A (en) | 2001-08-27 |
CN1227004C (zh) | 2005-11-16 |
NO20023879L (no) | 2002-08-15 |
EP2033633A2 (en) | 2009-03-11 |
CA2398691A1 (en) | 2001-08-23 |
WO2001060348A2 (en) | 2001-08-23 |
US20010047000A1 (en) | 2001-11-29 |
US20030119718A1 (en) | 2003-06-26 |
NO20023879D0 (no) | 2002-08-15 |
IL151014A0 (en) | 2003-02-12 |
TWI235655B (en) | 2005-07-11 |
MXPA02007639A (es) | 2004-08-23 |
US6528511B2 (en) | 2003-03-04 |
EP2033633A3 (en) | 2009-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL151014A0 (en) | Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure | |
HK1073441A1 (zh) | 部分脂肪酸氧化抑制劑如雷諾嗪用於治療糖尿病 | |
HK1069815A1 (en) | Omega-aminoalkylamides of r-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells | |
AU8707601A (en) | Heart support to prevent ventricular remodeling | |
EP1412023A4 (en) | METHOD AND DEVICE IN-VIVO FOR IMPROVING THE DIASTOLIC FUNCTION OF THE LEFT VENTRICLE | |
AU2001249881A1 (en) | Method of treating the heart | |
IL160065A0 (en) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
ZA200107122B (en) | Treatment of acne using lipoic acid. | |
PL363269A1 (en) | Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy | |
HK1048443A1 (en) | Fatty acid derivative for the treatment of external secretion disorders | |
NO20031797L (no) | Heteroarylalkylpiperazin-derivater som fettsyreoksidasjonsinhibitorer | |
PL362984A1 (en) | Compounds useful in the treatment of inflammatory diseases | |
IL149251A0 (en) | Diagnosis and treatment of cardiovascular conditions | |
IL154802A0 (en) | New oxabispidine compound useful in the treatment of cardiac arrhythmias | |
IL151596A0 (en) | Use of lactic acid bacterium for the treatment of peritonitis | |
IL147363A0 (en) | Ppar delta inhibitor for the treatment of cardiovascular diseases | |
GB0111594D0 (en) | Pipecolnic acid derivatives method of manufacturing the same and therapeutic agents containing these compounds | |
GB9922710D0 (en) | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis | |
AU2001289723A1 (en) | Novel use of difluoromalonic acid esters | |
GB0018320D0 (en) | Method of safely oxidizing fat molecules in vivo | |
SI1585513T1 (sl) | Uporaba dokosaheksaenojske kisline kot aktivne snovi za zdravljenje lipodistrofije | |
EE04960B1 (et) | Meetod arliminometlkarbamiinhappeestrite valmistamiseks | |
AU2001228481A1 (en) | Oxidation of o-xylol to produce o-tolyl acid | |
GB0017435D0 (en) | 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acid derivatives | |
SI1296670T1 (sl) | Teraprvtske kombinacije mascobnih kislin |